Meiragtx Holdings Plc (MGTX)

$8.72 -0.03 (-0.34%)
Market Cap 703.91M
Revenue (ttm) 33.28M
Net Income (ttm) -147.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -444.08%
Debt to Equity Ratio 24.92
Volume 407,600
Avg Vol 368,918
Day's Range N/A - N/A
Shares Out 80.45M
Stochastic %K 64%
Beta 1.34
Analysts Strong Sell
Price Target $23.83

Company Profile

MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 860 7985
Address:
450 East 29th Street, 14th Floor, New York, United States
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 9:21 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MGTX Current Share Price: $8.63 Contracts: $MGTX April 17, 2026 $10 Calls Scale in: $1.77- $2.16 Scale out: $2.75-$3.53 Can Easily Capture: 60% ROI Blended DTE: 176 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
ErnieWorthing84
ErnieWorthing84 Oct. 24 at 2:48 PM
$MGTX Hmm, Lilly just bought an ocular gtx focused on intravitreal delivery...
1 · Reply
Helpmrwizard
Helpmrwizard Oct. 23 at 4:39 AM
$MGTX did I hear correctly (panel webcast) that Zandy expects JNJ to file “nearish term?” If successfully approved, that’s $5/ share cash plus mfgring sales; I doubt they would file if they were not confident of approval
1 · Reply
stockanalysis_
stockanalysis_ Oct. 22 at 9:11 PM
After Hours Losers: $AZI $BENF $AIRE $MGTX $YYAI Bookmark this screener: https://stockanalysis.com/markets/afterhours/losers/?ref=saveontrading
0 · Reply
RunnerSignals
RunnerSignals Oct. 22 at 8:33 PM
Triple-digit targets on $MGTX $DCTH while $DKNG $MGM $FLUT getting love too 🎯 Upgrade szn hits different 🔥 https://stocksrunner.com/news/2025-10-22-stock-upgrades-today-worth-watching-for-active-traders
0 · Reply
BigDaddy_LongTrades
BigDaddy_LongTrades Oct. 22 at 6:27 PM
$MGTX well i took a chance and sold all on the pop because sadly Ive seen this story before w Meira... now the question is where do I rebuy at?
1 · Reply
ErnieWorthing84
ErnieWorthing84 Oct. 22 at 12:18 PM
$MGTX Use your 🧠. Don't be a 🐑💩
0 · Reply
waterlock
waterlock Oct. 22 at 5:44 AM
$MGTX What a nice day for $MGNX $MGTX
0 · Reply
rulesmoney
rulesmoney Oct. 22 at 2:49 AM
$MGTX Read the footnotes to the Form 4. The sale is NOT a one-time sale. It is part of a Rule 10b5-1 trading plan adopted by the CFO over a year ago. He sells shares every quarter. Lots of executives in lots of companies do this to keep from having all their eggs in one basket.
0 · Reply
transfercoefficient
transfercoefficient Oct. 22 at 1:31 AM
$MGTX CFO selling a few shares. Small but still annoying.
0 · Reply
Latest News on MGTX
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Oct 7, 2025, 8:00 AM EDT - 18 days ago

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

MeiraGTx: Hologen Partnership Makes Parkinson's Gene Therapy Vital

Sep 25, 2025, 3:48 AM EDT - 4 weeks ago

MeiraGTx: Hologen Partnership Makes Parkinson's Gene Therapy Vital

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

Aug 14, 2025, 8:00 AM EDT - 2 months ago

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

May 13, 2025, 4:30 PM EDT - 5 months ago

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

May 13, 2025, 8:00 AM EDT - 5 months ago

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease

May 9, 2025, 8:00 AM EDT - 6 months ago

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease

Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more

Apr 29, 2025, 7:11 AM EDT - 6 months ago

Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more

MeiraGTx Holdings: Gaining Regulatory Focus

Mar 25, 2025, 10:50 AM EDT - 7 months ago

MeiraGTx Holdings: Gaining Regulatory Focus

MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars

Mar 13, 2025, 9:51 AM EDT - 8 months ago

MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

Mar 13, 2025, 8:00 AM EDT - 8 months ago

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process

Mar 13, 2025, 7:30 AM EDT - 8 months ago

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

Feb 21, 2025, 6:30 AM EST - 8 months ago

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value

Jan 22, 2025, 4:09 PM EST - 9 months ago

MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

Jan 22, 2025, 8:30 AM EST - 9 months ago

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

MeiraGTx Holdings: Behind The Recent Rally

Dec 3, 2024, 2:18 PM EST - 11 months ago

MeiraGTx Holdings: Behind The Recent Rally

MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings

Oct 15, 2024, 1:32 PM EDT - 1 year ago

MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings

MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference

Oct 9, 2024, 4:30 PM EDT - 1 year ago

MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference

MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results

Aug 12, 2024, 7:05 AM EDT - 1 year ago

MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results

MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi

Aug 12, 2024, 7:03 AM EDT - 1 year ago

MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi

MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts

Jul 15, 2024, 11:02 AM EDT - 1 year ago

MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

May 9, 2024, 8:00 AM EDT - 1 year ago

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

MeiraGTx to Participate in Upcoming Investor Conferences

Apr 24, 2024, 4:30 PM EDT - 1 year ago

MeiraGTx to Participate in Upcoming Investor Conferences

MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference

Apr 18, 2024, 4:30 PM EDT - 1 year ago

MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference

MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates

Mar 14, 2024, 8:30 AM EDT - 1 year ago

MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates

MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met

Feb 15, 2024, 8:23 AM EST - 1 year ago

MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met

MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million

Dec 21, 2023, 7:00 AM EST - 2 years ago

MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

Nov 14, 2023, 8:00 AM EST - 2 years ago

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

MeiraGTx shares jump as Sanofi invests in gene therapy

Oct 30, 2023, 8:28 AM EDT - 2 years ago

MeiraGTx shares jump as Sanofi invests in gene therapy

SNY

MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities

Oct 30, 2023, 7:30 AM EDT - 2 years ago

MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities

MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

Oct 24, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

MeiraGTx Reports Second Quarter 2023 Financial and Operational Results

Aug 10, 2023, 8:00 AM EDT - 2 years ago

MeiraGTx Reports Second Quarter 2023 Financial and Operational Results

MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology

Aug 1, 2023, 9:10 AM EDT - 2 years ago

MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology

MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing

Jul 19, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing

MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Jun 27, 2023, 7:30 AM EDT - 2 years ago

MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company's Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27,

Jun 22, 2023, 4:01 PM EDT - 2 years ago

MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company's Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27,

MeiraGTx Reports First Quarter 2023 Financial and Operational Results

May 11, 2023, 8:00 AM EDT - 2 years ago

MeiraGTx Reports First Quarter 2023 Financial and Operational Results

MeiraGTx Announces $60 Million Private Placement of Ordinary Shares

May 3, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces $60 Million Private Placement of Ordinary Shares

MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

Apr 21, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

Mar 14, 2023, 8:00 AM EDT - 2 years ago

MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022

Dec 8, 2022, 4:30 PM EST - 3 years ago

MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022

MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress

Oct 4, 2022, 8:00 AM EDT - 3 years ago

MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress

Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)

Oct 1, 2022, 10:00 AM EDT - 3 years ago

Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)

MeiraGTx's Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government

Sep 16, 2022, 2:00 AM EDT - 3 years ago

MeiraGTx's Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government

MeiraGTx Reports Second Quarter 2022 Financial and Operational Results

Aug 11, 2022, 8:30 AM EDT - 3 years ago

MeiraGTx Reports Second Quarter 2022 Financial and Operational Results

MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities

Aug 3, 2022, 8:00 AM EDT - 3 years ago

MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities

MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) compared to

Jun 28, 2022, 7:00 AM EDT - 3 years ago

MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) compared to

MeiraGTx Reports First Quarter 2022 Financial and Operational Results

May 12, 2022, 8:00 AM EDT - 3 years ago

MeiraGTx Reports First Quarter 2022 Financial and Operational Results

MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

May 4, 2022, 4:01 PM EDT - 3 years ago

MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

MeiraGTx to Participate in Upcoming Investor and Scientific Conferences

Apr 19, 2022, 4:30 PM EDT - 3 years ago

MeiraGTx to Participate in Upcoming Investor and Scientific Conferences

MeiraGTx Reports Fourth Quarter and Full Year 2021 Financial and Operational Results

Mar 10, 2022, 8:00 AM EST - 3 years ago

MeiraGTx Reports Fourth Quarter and Full Year 2021 Financial and Operational Results

LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 9:21 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MGTX Current Share Price: $8.63 Contracts: $MGTX April 17, 2026 $10 Calls Scale in: $1.77- $2.16 Scale out: $2.75-$3.53 Can Easily Capture: 60% ROI Blended DTE: 176 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
ErnieWorthing84
ErnieWorthing84 Oct. 24 at 2:48 PM
$MGTX Hmm, Lilly just bought an ocular gtx focused on intravitreal delivery...
1 · Reply
Helpmrwizard
Helpmrwizard Oct. 23 at 4:39 AM
$MGTX did I hear correctly (panel webcast) that Zandy expects JNJ to file “nearish term?” If successfully approved, that’s $5/ share cash plus mfgring sales; I doubt they would file if they were not confident of approval
1 · Reply
stockanalysis_
stockanalysis_ Oct. 22 at 9:11 PM
After Hours Losers: $AZI $BENF $AIRE $MGTX $YYAI Bookmark this screener: https://stockanalysis.com/markets/afterhours/losers/?ref=saveontrading
0 · Reply
RunnerSignals
RunnerSignals Oct. 22 at 8:33 PM
Triple-digit targets on $MGTX $DCTH while $DKNG $MGM $FLUT getting love too 🎯 Upgrade szn hits different 🔥 https://stocksrunner.com/news/2025-10-22-stock-upgrades-today-worth-watching-for-active-traders
0 · Reply
BigDaddy_LongTrades
BigDaddy_LongTrades Oct. 22 at 6:27 PM
$MGTX well i took a chance and sold all on the pop because sadly Ive seen this story before w Meira... now the question is where do I rebuy at?
1 · Reply
ErnieWorthing84
ErnieWorthing84 Oct. 22 at 12:18 PM
$MGTX Use your 🧠. Don't be a 🐑💩
0 · Reply
waterlock
waterlock Oct. 22 at 5:44 AM
$MGTX What a nice day for $MGNX $MGTX
0 · Reply
rulesmoney
rulesmoney Oct. 22 at 2:49 AM
$MGTX Read the footnotes to the Form 4. The sale is NOT a one-time sale. It is part of a Rule 10b5-1 trading plan adopted by the CFO over a year ago. He sells shares every quarter. Lots of executives in lots of companies do this to keep from having all their eggs in one basket.
0 · Reply
transfercoefficient
transfercoefficient Oct. 22 at 1:31 AM
$MGTX CFO selling a few shares. Small but still annoying.
0 · Reply
Doozio
Doozio Oct. 21 at 6:18 PM
$MGTX 🐒🍌🧠⏰♾️
0 · Reply
DARKP00L
DARKP00L Oct. 21 at 5:43 PM
$MGTX 13:40 on Oct. 21 2025 Raymond James Initiates Coverage On MeiraGTx Hldgs with Strong Buy Rating, Announces Price Target of $29 #tradeideas
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 5:40 PM
Raymond James has adjusted their stance on MeiraGTx Hldgs ( $MGTX ), setting the rating to Strong Buy with a target price of 29.
0 · Reply
stockpicker63
stockpicker63 Oct. 21 at 3:24 PM
$MGTX Now +5.7%
0 · Reply
ErnieWorthing84
ErnieWorthing84 Oct. 21 at 3:18 PM
$MGTX
0 · Reply
stockpicker63
stockpicker63 Oct. 21 at 2:26 PM
$MGTX appears to be in a favourable technical posture for a potential breakout, given its consolidation, support/resistance structure, and positive momentum signals. It’s on the radar.
0 · Reply
ErnieWorthing84
ErnieWorthing84 Oct. 21 at 1:44 PM
$MGTX Expect XLRP "to be filed in the near-ish term"
1 · Reply
vu_jade
vu_jade Oct. 20 at 10:56 PM
$MGTX bullish look
0 · Reply
notreload_ai
notreload_ai Oct. 20 at 9:04 PM
Raymond James initiates $MGTX with Strong Buy rating and $29 price target, highlighting company's manufacturing platform and two major commercial opportunities in xerostomia and Parkinson's disease. https://notreload.xyz/raymond-james-initiates-meiragtx-strong-buy-rating/
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 20 at 7:46 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MGTX Current Share Price: $7.75 Contracts: $MGTX April 17, 2026 $10 Calls Scale in: $0.75- $0.92 Scale out: $1.17-$1.51 Can Easily Capture: 60% ROI Blended DTE: 180 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
ErnieWorthing84
ErnieWorthing84 Oct. 20 at 6:35 PM
$MGTX https://www.linkedin.com/posts/genetherapy-biotech-innovation-share-7386098097644498944-buZw?utm_source=share&utm_medium=member_desktop&rcm=ACoAAFicp8EBCpjqvJoEMU3md0X2SKAJxYKoJms
1 · Reply
slinghook67
slinghook67 Oct. 19 at 2:55 PM
$MGTX Here’s something that I found very interesting. Elemer Piros (Ph. D and Managing Director, Healthcare Equity Research @ Lucid Capital Management), was rated in separate years by the Wall Street Journal and the Financial Times as the #1 Biotech analyst based on stock portfolio performance. He also has a Ph. D from UCLA in Neuroscience. I share all of this because his current price target on MeiraGTx is $50.
2 · Reply